Pelosi’s radical plan would leave Alzheimer’s patients behind

Last month, House Speaker Nancy Pelosi unveiled a radical drug pricing plan, H.R. 3, that could jeopardize the development of innovative treatments for some of the most challenging diseases and leave...
Read More
Event tomorrow: Maintaining America’s leadership in access and innovation

Each year, biopharmaceutical companies invest nearly $100 billion in the discovery of new treatments and cures. Despite a challenging research and development (R&D) process, consistently high levels...
Read More
What they are saying: Broad opposition to Pelosi’s radical drug pricing plan

Recently, House Speaker Nancy Pelosi unveiled a radical drug pricing plan that would be the wrong approach for patients, the U.S. health care system, economy, and American innovation. An increasing...
Read More
On Manufacturing Day, a closer look at the biopharmaceutical sector’s contributions

Each year, the first Friday in October marks Manufacturing Day, an annual recognition of the critical role manufacturing-intensive industries play in powering innovation and generating jobs and...
Read More
By the Numbers: Pelosi’s radical plan puts America’s economy and jobs at risk

We already know that the radical drug pricing plan unveiled last week by House Speaker Nancy Pelosi is the wrong approach for patients, the U.S. health care system, and American innovation. But what...
Read More
World Trade Month: How we can expand world-class pro-innovation standards

May is World Trade Month—a celebration of the industries that import and export goods and services around the world. The month offers a good opportunity to examine the significance of international...
Read More
New Report: Advanced manufacturing powering innovative biopharmaceuticals

The science-based advanced manufacturing infrastructure of the biopharmaceutical industry is critical to fueling the innovation necessary to bring new treatments and cures to patients. With a...
Read More
Clinical trials impact state economies

A new report from TEConomy Partners, supported by PhRMA, provides estimates of industry-sponsored clinical trial activity in each of the 50 states, including the number of trials active, the number...
Read More
Biopharmaceutical venture capital is spurring innovation and economic growth

The biopharmaceutical ecosystem has helped make the U.S. the global leader in biomedical innovation today. An important part of this ecosystem is the thousands of small startup biopharmaceutical...
Read More
PhRMA member companies R&D investments hit record high in 2017 - $71.4 billion

PhRMA member companies invested $71.4 billion in research and development (R&D) in 2017, the highest level of investment on record, according to the 2018 PhRMA member annual survey, released in...
Read More